0000899243-17-002061.txt : 20170126
0000899243-17-002061.hdr.sgml : 20170126
20170126200241
ACCESSION NUMBER: 0000899243-17-002061
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170126
FILED AS OF DATE: 20170126
DATE AS OF CHANGE: 20170126
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jounce Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640455
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1030 MASSACHUSETTS AVE.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
BUSINESS PHONE: 857-259-3840
MAIL ADDRESS:
STREET 1: 1030 MASSACHUSETTS AVE.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hadley Harbor Master Investors (Cayman) L.P.
CENTRAL INDEX KEY: 0001641080
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37998
FILM NUMBER: 17551396
BUSINESS ADDRESS:
STREET 1: ELIAN FIDUCIARY SERVICES (CAYMAN) LTD
STREET 2: 89 NEXUS WAY, CAMANA BAY
CITY: GRAND CAYMAN
STATE: E9
ZIP: KY1-9007
BUSINESS PHONE: 617-790-7163
MAIL ADDRESS:
STREET 1: ELIAN FIDUCIARY SERVICES (CAYMAN) LTD
STREET 2: 89 NEXUS WAY, CAMANA BAY
CITY: GRAND CAYMAN
STATE: E9
ZIP: KY1-9007
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2017-01-26
0
0001640455
Jounce Therapeutics, Inc.
JNCE
0001641080
Hadley Harbor Master Investors (Cayman) L.P.
C/O WELLINGTON MANAGEMENT COMPANY LLP
280 CONGRESS STREET
BOSTON
MA
02210
0
0
1
0
No securities are benefically owned
0
D
Series B Convertible Preferred Stock
Common Stock
719476
D
Each share of Series B convertible preferred stock is convertible into 0.271003 shares of common stock at the option of the reporting person or upon the occurrence of certain events. All outstanding shares of Series B convertible preferred stock are expected to convert into shares of common stock immediately prior to the amendment and restatement by Jounce Therapeutics, Inc. of its certificate of incorporation, provided the amendment and restatement occurs prior to, and on the same day as, the closing of its initial public offering at an initial public offering price that results in at least $35 million of gross proceeds, after deducting the underwriting discount and commissions, to Jounce Therapeutics, Inc.
Hadley Harbor Master Investors (Cayman) L.P., By: Wellington Alternative Investments LLC, as General Partner, /s/ Matthew N. Shea, Title: Managing Director and Counsel
2017-01-24